Video

Dr. Hoshida on Molecular Subtyping in HCC

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

Yujin Hoshida, MD, PhD, associate professor of internal medicine, University of Texas Southwestern Medical Center, discusses molecular subtyping in hepatocellular carcinoma (HCC).

Over the past decade, multiple subtypes of HCC have been identified using advanced genomic technology, says Hoshida. The research suggests that there may be a link between how patients with different molecular subtypes of HCC respond to different therapeutic options, explains Hoshida.

Understanding what patient subtype responds best to what treatment may be a more efficient way to personalize therapy rather than to direct specific drugs to multiple targets, concludes Hoshida.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center